Skip to content
CancerIndex

Publication

Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

Authors not recorded

Blood2010PMID 20421455stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (3)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 3

Curated evidence

Evidence citing this paper (1)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
20421455
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
IDH2 Mutation1
(prognostic)Acute Myeloid LeukemiaCURATED_BROADERPrognosticBDoes Not Support N/A3accepted
EID328

In patients with IDH2 R140 and R172 mutation, the presence of mutation does not impact overall survival or disease free survival.

PMID 20421455 · Thol et al., 2010 · Open in CIViC

civic